AXL inhibitors selected by molecular docking: Option for reducing SARS-CoV-2 entry into cells
Pubblicato online: 13 apr 2022
Pagine: 329 - 343
Accettato: 18 ott 2021
DOI: https://doi.org/10.2478/acph-2022-0024
Parole chiave
© 2022 Octavio Galindo-Hernández et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The COVID-19 pandemic is ongoing and the benefit from vaccines is still insufficient since COVID-19 continues to be dia g-nosed in vaccinated individuals. It is, therefore, necessary to propose specific pharmacological treatments against COVID-19. A new therapeutic target on the human cellular membrane is AXL (